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Abstract
Background: Coronaviruses (CoVs) belong to a family that comes under the order 
“Nidovirales.” Nidovirales order includes the viruses that use a nested set of mRNAs 
for their replication. CoV disease 2019 (COVID)-19 is a βCoV-2, CoV of the same 
subgenus as severe acute respiratory syndrome (SARS) virus, but in a different clad. 
The constitution of the receptor-binding gene region is very like to that of the SARS-
CoV, and the virus has been demonstrated to utilize the same receptor, the angiotensin-
converting enzyme 2, for entrance into respiratory cells. There are presently no drugs or 
vaccinations that are known to be successful for SARS-CoV-2 management or preventing 
the spread as per various major health officials. Aim: This review describes various 
drug treatment options available against COVID-19. It focuses on the use virology of 
SARS-COV2, potential drugs that can be utilized to treat COVID-19 infection, their 
dosages, advantages, side effects, and indications. Conclusion: As there are no definitive 
treatment modes accessible to cure SARS-COV2 infection to this date, drug repurposing 
can provide effective tool to combat against COVID-19 until definitive drugs or 
vaccines discovered to treat SARS-CoV2 infection. Various antiviral, antiparasitic, and 
antimalarial drugs, antibodies, Vitamin C, Vitamin D, melatonin hormone, etc., are 
effective to reduce viral load of COVID-19. Clinical Significance: Drug repurposing 
and previous or recent clinical experiences with CoV infection provide an efficient 
weapon to COVID-19 infection. They are effective in not only reducing viral load of 
COVID-19 infection but also minimize the symptoms related to SARS.
Keywords: Coronavirus disease 2019, Coronaviruses, Outbreak, Respiratory illness, Transmission, 
Infection control and management
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Background
Coronaviruses (CoVs) are the predominant genus of 
Nidovirales-related viruses, comprising Coronaviridae, 
Arteriviridae, Mesoniviridae, and Roniviridae groups. CoV virion 
is circular with a diameter of nearly 125 nm. Its most conspicuous 
characteristic of CoV is the club-shaped spiked figures emerging 
from the coating of the virion. These spikes are a distinct 
peculiarity of the virion and lend them the expression of a solar 
corona contributing to the phrase CoV.[1] Coronaviridae covers a 
broad range of host and carriers, infecting many mammalian and 
avian species/subspecies, this may affect the upper respiratory, 
gastrointestinal, hepatic, and central nervous system through a 
number of diseases.[2]
Severe acute respiratory syndrome (SARS)-CoV, Class 2b-β 
CoV, was revealed as the potential culprit of the 2002–2003 
epidemic of SARS throughout the Guangdong territory of China. 
In a cluster of extensively pathogenic respiratory infections in 
Saudi Arabia as well as other Middle East countries during 2012, 
the Middle East respiratory CoV syndrome (MERS-CoV) has 
been defined as the potential culprit of yet another novel human 
CoV.[3]
On December 31, 2019, the Wuhan Health Commission in the 
Republic of China’s Hubei Province notified the National Health 
Commission, China Centers for Disease Control and Prevention 
(CDC), and the World Health Organization (WHO) of a series 
of 27 cases of unexplained etiological pneumonia. Leaks have been 
predominantly tracked to the Huanan Seafood Wholesale Market in 
Wuhan that trades fish and a myriad of livestock species comprising 
chickens, bats, marmots, and snakes.[4] By January 7, 2020, 
Chinese CDC officials had isolated SARS-CoV-2. On February 
11, the WHO officially named the disease as the CoV disease 2019 
(COVID-19).[5] The WHO also announced a global emergency on 
January 31 due to increasing concern about its rapid expansion and 
the disease became listed as a pandemic by March 11.[6]
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According to the world's leading health authorities, there are 
currently no known medicines or vaccines is neither successful 
in reducing viral load of  SARS-CoV-2 nor in preventing its 
spread. Within clinical trials and compassionate use guidelines, 
numerous different compounds are used relying on in vitro 
activity (against SARS-CoV-2 or associated viruses) and on 
constrained clinical knowledge. There was no proven efficacy for 
any drug therapy.[7] As of April 13, 2020, COVID-19 has been 
recognized in 196 countries, with a total of 1,876,707 laboratory-
confirmed cases, 435,591 recovered, and 116,789 deaths. Till 
this date, 9352 laboratory-confirmed cases, 980 recovered, 
and 324 deaths were reported by Indian Council of Medical 
Research in India.
Literature Search
This narrative review discusses the relevant literature, including 
updated studies, case series, protective measure, treatment 
guidelines, and the implications for practice with respect to 
(novel CoV, nCoV) infection. We performed a literature 
search using ProQuest, Medline, PubMed, and Google Scholar 
search engines. The search terms used were COVID-19, CoV, 
outbreak, “respiratory illness,” “transmission,” and “infection 
control and management.” A total of 150 articles were selected 
after citation screening and removing duplicates from search 
databases. Sixty-six articles then selected for inclusion based on 
full text publication after initial review. Forty-three articles were 
included from the searched articles on the basis of description 
of methods and content, hence, 23 articles which lack the given 
inclusion criteria were excluded from the study.
Discussion
Virology
CoVs belong to a family that comes under the order “Nidovirales.” 
Nidovirales order includes the viruses that use a nested set of 
mRNAs for their replication. Further, the CoV subfamily has 
four genera (alpha, beta, gamma, and delta coronaviruses).
Beta-CoVs that carry the disease comprise HCoV-HKU1, 
HCoV-OC43, MERS-CoV syndrome, severe acute respiratory 
CoV syndrome (SARS-CoV), and SARS-CoV-2.[8] Genomic 
and phylogenic research has shown that COVID-19 is a βCoV-2, 
CoV of the same subgenus as SARS virus, but in a different clad. 
The constitution of the receptor-binding gene region is very like 
to that of the SARS-CoV, and the virus has been demonstrated 
to utilize the same receptor, the angiotensin-converting enzyme 
2 (ACE2), for entrance into respiratory cells.[9] The another one-
third of the genome contains four structural proteins (spike [S], 
envelope [E], membrane [M], nucleocapside [N], and some 
other helper proteins. The spike protein plays an important role 
in virus entry into the host. The spike protein are responsible 
for Initial interactions between the S1 domain and its host 
receptor (ACE2) in case of SARS-CoV and  SARS-CoV-2.[10] 
The E protein is the smallest (8.4–12 kDa size) TM structural 
protein of CoV. The E protein plays a crucial role in the 
morphogenesis of viruses, notably during acquisition as well as 
egress. Maintenance of the shape of the viral envelope is the most 
important function of the M protein, and the M protein performs 
this job by interacting with other CoV proteins. M protein also 
takes part in the sensitization of the host by the virus.[11]
Formation and maintenance of the ribonucleoprotein 
complex are the most important functions of the N protein, it 
often controls viral RNA replication and transcription, and in 
host, it inhibits protein translation through EF1α-mediated 
action. Hemagglutinin-esterase is present in the envelope of CoV, 
more specifically among beta-coronaviridiae. The HE is a marker 
of CoV and influenza virus evolution.[12] E protein plays a crucial 
role in the assembling and release of viruses. In addition, the E 
proteins have several other roles, like the activation of the ion 
channel necessary for SARS-CoV pathogenesis, and presumably 
SARS-CoV-2. The presence of this furin-like cleavage region 
in SARS-CoV-2 promotes the priming of S proteins and may 
improve the performance of SARS-CoV-2 dissemination.[8,9]
Treatment and management
Drug repurposing is a feasible, quick, and expense effective 
approach that can solve the obstacles of the conventional de novo 
drug discovery and production by addressing various diseases 
and disorders. Drug repurposing is the method of finding new 
applications for existing or candidate drugs and is a successful 
drug development technique.[13]
As per the WHO, the CDC, and the Food and Drug 
Administration (FDA), there are presently no medicines or 
vaccinations that are believed to be likely to succeed for SARS-
CoV-2 management or preventing the spread.[7] The only 
alternative available is to use wide spectrum antiviral drugs such 
as nucleoside analogs as well as human immunodeficiency virus 
(HIV) protease inhibitors that can attenuate viral infection 
before the actual antiviral is available.[14]
Pharmacological management of young, stable patients with 
minor symptoms and no inherent comorbid circumstances is 
usually not recommended.[7]
The People’s Republic of China’s National Health 
Commission has supported the use of chloroquine phosphate 
to treat COVID-19 patients, in its revised guidelines for the 
prevention, diagnosis, and treatment of pneumonia developed 
due to COVID-19 infection in the vast populous country (Gao 
et al., 2020; Lin and Li, 2020).[13]
Passive antibody transfer is one of the most effective and 
traditional tools used in most of the infectious outbreaks which 
is the use of serum of patients who just recovered from the 
active viral infection to treat patients who contract in future.[15] 
Monoclonal antibodies will be used in passive immunotherapy 
as powerful biotherapeutics to overpower the SARS-CoV-2and 
to control the harmful outcomes of COVID-19. Intravenous use 
of immunoglobulins can prove helpful in the therapy of SARS-
CoV-2-induced pulmonary inflammation.[13]
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Hormone – melatonin
Viruses trigger an eruption of reactive oxygen molecule and the 
cure is melatonin a renowned antioxidant. Melatonin prevents 
the programmed death of cells that coronaviruses cause, causing 
significant damage to the lungs. Coronavirus triggers lung 
inflammation through inflammasome activity and melatonin is 
known to avid this process. One of the most severe complications 
after COVID-19 is fibrosis of the lungs which can be prevented 
by melatonin administration.[16]
Melatonin is a bioactive agent with a variety of health booster 
activity (N-acetyl-5-methoxytryptamine); melatonin was in 
fact commonly used in sleep disorder diagnosis, respiratory 
diseases and viral delirium, and atherosclerosis. Melatonin does 
not have antiviral capacity, but it can indirectly exert antiviral 
effect through anti-inflammatory, anti-oxidation, and immunity 
boosting capacity.[17] During drug trials, melatonin is given in 
severely ill intensive care unit (ICU) patients in the dosages of 
3 mg, 6 mg, and 10 mg through oral rote showed adequate safety 
compared with placebo. Interestingly, even though melatonin 
was administered to individuals for a month at a dosage of 1 g/d, 
there were no detrimental treatment observations.[18] Thus, 
melatonin can serve as a potential adjuvant treatment along with 
combination of the antiviral drugs lopinavir/ritonavir.
Protein – lactoferrin (Lf)
Lf is the highly conserved pleiotropic iron-binding transferrin of 
glycoprotein family, which is expressed and secreted by glandular 
cells and found in most body fluids. Lfs anti-inflammatory and 
immunomodulatory role appears to be capable of moderating 
the response of the host to pathogens and having dual 
capacity to activate the immune system to combat pathogenic 
infiltration while at the same time avoiding adverse immune 
and inflammatory responses.[19] Lf prone human pathogenic 
viruses known to be suppressed from Lf comprise DNA and 
RNA viruses: Cytomegaloviruses, herpes simplex viruses, HIV, 
rotaviruses, polioviruses, respiratory syncytial viruses, hepatitis B 
and C (HCV) viruses, parainfluenza viruses, alpha viruses, hanta 
viruses, human papilloma viruses, adenoviruses, enteroviruses 
71, echoviruses 6, influenza A viruses, and Japanese viruses. 
Lf is a naturally produced and non-toxic glycoprotein tested 
against a wide array of viruses including SARS-CoV that is 
genetically similar to COVID-19-causing SARS-CoV-2.[20] Lf 
doses ranging from 100 mg to 4.5 g a day for various indications 
without apparent toxicities. Newer formulations of Lf including 
encapsulation and liposomalization have been explored.[21] 
Reportedly, zinc-saturated Lf has a much more potent antiviral 
activity. This is of particular relevance in COVID-19 as zinc 
supplementation has been proposed as a possible supplemental 
intervention for the disease.[22]
Passive antibody – COVID-19 convalescent plasma
Passive antibody transfer is one of the most efficient and 
conventional technique used in nearly all infectious outbreaks 
which utilizes of serum of patients who just recovered from the 
active viral infection to treat patients who contract in future. 
Patients recovering through active viral infections generate 
a polyclonal immune system response to varying SARS-
CoV-2 antigens, thus counteracting active viral infections, and 
hence, convalescent phase plasma can be used as a therapeutic 
alternative.[15] Patients eligible under the emergency investigatory 
New Drug Applications: (I) Must have laboratory confirmed 
COVID-19. (II) Should have devastating or instantaneous life-
threatening COVID-19 severe infection described as dyspnea, 
respiratory rate 30 breaths/min or elevated, blood oxygen 
saturation 93% or below, arterial oxygen partial pressure of less 
than 300 inspired oxygen ratio, and/or pulmonary infiltration of 
more than 50% in <24 to 48 h. (III) Life-threatening condition 
described as respiratory failure, septic shock, malfunction or 
failure of multiple organs. (IV) Must give informed consent.[7]
Neutralizing antibody: Tocilizumab
Tocilizumab is an interleukin-6 (IL-6) receptor-inhibiting 
monoclonal antibody. Tocilizumab inhibits IL-6-mediated 
signaling by competitively binding to both soluble and 
membrane-bound IL-6 receptors. IL-6 is a pro-inflammatory 
cytokine implicated in myriad physiological processes, such 
as the induction of T-cells, the initiation of immunoglobulin 
generation, stimulate hepatic acute-phase protein synthesis, and 
the multiply and differentiate hematopoietic precursors. IL-6 
is produced by myriad types of cells comprising T- and B-cells, 
lymphocytes, monocytes, and fibroblasts.[23] Tocilizumab first 
became authorized by the FDA for the treatment of rheumatoid 
arthritis in 2010. It received FDA approval for severe or life-
threatening chimeric antigen receptor T-associated cytokine 
release syndrome in 2017 due to its efficacy and safety profile.[13] 
Xu et al. retrospective assessment analyzed 21 patients in whom 
tocilizumab was incorporated to standard COVID-19 therapy. 
Early data postulate that tocilizumab may have therapeutic 
benefit as an adjunct treatment. Clinical symptoms, computed 
tomography opacity changes, lymphocyte percentage, and 
C-reactive protein levels all improved in these patients.[24] The 
prescribed dose is 4–8 mg/kg or 400 mg of the typical IV dose 
once and may be repeated in 12 h (not to reach a maximum dose 
of 800 mg). Possible complications are risk of GI perforation, risk 
of hepatotoxicity, caution in patients with thrombocytopenia 
and neutropenia, and infusion-related reactions.[7]
Antibiotics – teicoplanin
Teicoplanin, a glycopeptide antibiotic routinely used to treat 
bacterial infections, currently used in the treatment of Gram-
positive bacterial infections, especially staphylococcal infections. 
It has usefulness against myriad viruses like those of Ebola virus, 
influenza virus, flavivirus, hepatitis C virus, and HIV and even 
coronavirus including MERS-CoV as well as SARS-CoV.[25] 
According to Zhou et al. in coronaviruses, teicoplanin works 
at the initial stage of the viral life cycle by impeding the low 
pH cleavage of the viral spike protein by cathepsin L in late 
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endosomes, prohibiting the emergence of genomic viral RNA 
and the progression of the virus replication process.[26]
Zhang et al. (2020) showed that teicoplanin has antiviral 
activity against SARS-CoV-2 in their study. The concentration 
of teicoplanin required to inhibit 50% of viruses (IC 50 ) in 
vitro was 1.66 μM, which is much lower than the concentration 
reached in human blood (8.78 μM for a daily dose of 400 mg).[27] 
Thus, teicoplanin may potential candidate for alternative drugs 
used against COVID-19.
Hormone – IgG
Immunoglobulin G has been prescribed as a treatment in 
critical patients with COVID-19. FcR plays a role in pulmonary 
inflammation; thus, blocking FcR activation will reduce 
inflammatory damage to COVID-19. Thus, intravenous use of 
immunoglobulins can prove efficient in the therapy of SARS-
CoV-2-induced pulmonary inflammation.[28] The efficacy of IV 
IG could be better if the IgG antibodies were collected from 
cases improved from SARSCoV-2 infection, so as to elevate 
the possibility of inactivating the virus, this process is called 
as “convalescent immune plasma” therapy. Immunity-based 
therapy with specific IgG antibodies along with antiviral drugs 
can be an alternative therapy against COVID-19 disease until 
better choices such as vaccine are accessible.[9]
Nucleotide analog – remdesivir (GS-5734)
Remdesivir is a new nucleotide analog that has effect against 
SARS-CoV-2 in vitro and linked coronaviruses (including SARS 
and MERS-CoV) both in vitro and in animal studies. Remdesivir 
is an investigatory monophosphoramidate prodrug of an 
adenosine analog.[9] Remdesivir is a monophosphoramidate 
prodrug of remdesivir-triphosphate (RDV-TP), an analogous 
adenosine, which functions as an RNA-dependent polymerase 
inhibitor. Remdesivir-TP competes with adenosine-
triphosphate for incorporation into nascent viral RNA chains. 
Once incorporated into the viral RNA at position i, RDV-TP 
terminates RNA synthesis at position i+3. Because RDV-TP 
does not cause immediate chain termination.[7]
Wang et al. in vitro study showed that remdesivir has significant 
activity against COVID-19 and a high genetic barrier to resistance. 
Remdesivir attains potent antiviral action toward SARS-CoV-2 
clinical isolates; (Half-maximum effective concentration [EC50] 
= 0.77 mcgM, Half-cytotoxic concentration [CC50] >100 mcgM, 
selective index [SI] >129.87).[14]
The drug has a long intracellular half-life that allows for once 
daily dosing. The dosage being investigated for COVID-19 has 
been 200 mg intravenously (IV) on day 1 followed by 100 mg IV 
each day for up to 10 days, infused for more than 30–60 min.[29]
Antivirals – lopinavir; ritonavir
Lopinavir is indeed a protease antagonist of HIV-1 provided in 
a fixed-dose combination with ritonavir (LPV/r), a formidable 
CYP3A4 inhibitor which “augments” lopinavir concentrations. 
Lopinavir tends to suppress the primary SARS-CoV-1 protease, 
which prohibits viral replication.[29] 
Lopinavir and ritonavir may bind to Mpro, a key enzyme for 
coronavirus replication. This may reduce CoV activity. Lopinavir; 
ritonavir in a dose of 400 mg/100 mg (2 capsules/tablets) by 
mouth twice a day for no more than 10 days is advised according 
to Chinese SARS-CoV-2 guidelines. In children’s weighing 15–
40 kg, the recommended dose is 10 mg/kg suspension by mouth 
twice daily as per to the United States guidelines.[30]
Safety concern regarding lopinavir, ritonavir has risk of 
cardiac arrhythmias (e.g., QT prolongation), caution in patients 
with hepatic disease or hepatitis, has myriad drug interactions. 
Cao et al. conducted comparative study of lopinavir; ritonavir 
used single agent or combined with either ribavirin or interferon 
(IFN)-α in mature patients hospitalized with severe COVID-19. 
There was a statistically significant difference in the time to 
clinical improvement between the two groups on day 14, but this 
result was not statistically significant on day 28. The morbidity 
at 28 days decreased by 5.8% and the duration of stay in the ICU 
minimized by 5 days with the lopinavir-ritonavir treatment.[31]
Vitamin D
Vitamin D is a steroid hormone which may be synthesized 
endogenously from the effect of UVB irradiation on skin or 
gained from exogenous dietary sources or supplements. Vitamin 
D is capable for reducing the immunity acquired and regenerating 
the endothelial lining. This may be desirable in decreasing the 
alveolar damage caused in ARDS.[32,33]
Systematic review and meta-analysis by Martineau et al. 
showed that level I findings (n = 11,321) revealed that 
Vitamin D supplementation has a 12% cumulative therapeutic 
benefit against bacterial and viral acute respiratory tract infection 
(adjusted OD = 0.88, p patients on a regular or weekly Vitamin D 
regimen relative to those consumed on a monthly Vitamin D 
bolus (adjusted OD = 0.81, P = 0.001).[32] Recommend intakes 
of Vitamin-D are 20 mg/day and 37.5–50 mg/day, respectively, 
for older adults as per the U.S. standards.[33]
Vitamin C
Vitamin C is well recognized for its antioxidant properties, which 
can harvest hazardous reactive oxygen species and thereby 
safeguard the cells as well as tissues of the body from oxidative 
damage and malfunction.[34] Vitamin C (L-ascorbic acid) has a 
defensive effect of high-dose intravenous Vitamin C (HDIVC) 
throughout ARDS-induced sepsis. Vitamin C enhances the 
conservation of the alveolar epithelial barrier and transcribes 
the protein channels (CFTR, aquaporin-5, ENaC, and Na+/K+ 
ATPase) to control alveolar fluid clearance.[33] Randomized trial 
involving Fowler et al., 167 patients with sepsis-related ARDS 
demonstrated that 4-day administration of ~15 g/day of IV 
Vitamin C could reduce mortality in such patients.[35]
A randomized controlled trial (RCT) was performed at the 
Zhongnan Hospital (NCT04264533) on February 14, 2020, 
to assess the clinical effectiveness and protection of Vitamin C 
Drug treatment of COVID-19 Hange and Devki
5
in SARSCoV-2 viral pneumonia. They believe that Vitamin C 
injection can enhance the prognosis of serious acute respiratory 
tract infections. The treatment arm requires a 7-day infusion of 
12 g Vitamin C (q12h) and the primary result tests ventilation-
free days. The expected time for fulfillment is September 2020.[33]
NSAID
That coronaviruses of the acute respiratory syndrome SARS-
CoV and SARS-CoV-2 bind to targeting cells by the 2-converting 
angiotensin enzyme (ACE 2), generated by lung, intestine, 
kidney, and blood vessel epithelial cells. Thus, the theory was 
raised that the management of diabetes and hypertension 
with ACE2 stimulant drugs raises the risk of severe and fatal 
COVID-19. Ibuprofen has been seen to upregulate ACE2 
receptors and SARS-CoV-2 utilizes it to reach the cells where it 
amplifies.[36]
Acetaminophen is first-line antipyretic. Repeated 
prescriptions typically involve oral acetaminophen, 10–15 mg/kg, 
4–6 times/day. There is no current evidence indicating that 
ibuprofen worsens the clinical course of COVID-1. The current 
standpoint of the WHO is to continue the use of ibuprofen as 
antipyretic agent.[9,33]
Corticosteroids
Corticosteroid medication for viral pneumonia is not suggested, 
but use has been taken into consideration in patients with 
refractory shock.[7]
The explanation behind all this strategy is that the 
corticosteroids extend the viral shedding cycle and sustain a 
widespread anti-inflammatory environment that minimizes 
ARDS occurrence, dyspnea, and severe pneumonia.[33]
The WHO/CDC advises them not be given in COVID-19 
disease with pneumonia except for there are other indications 
(e.g., exacerbation of chronic obstructive pulmonary disease, 
asthma, etc.). Chinese guidelines also advocate short-term 
therapy with low-to-moderate dose steroids for ARDS 
complication of COVID-19 disease. Corticosteroids can be 
administered in a short period of time (3–7 days). The suggested 
dose of methylprednisolone should not surpass 1–2 mg/kg/
day.[9]
Antiparasitic – ivermectin
Ivermectin is an FDA-approved broad-spectrum antiparasitic 
agent, shown to have antiviral activity against a broad range of 
viruses in vitro.[37]
A study by Leon et al. ivermectin has an antiviral effect 
toward clinical isolate SARS-CoV-2 in vitro, with a single 
dose capable of regulating viral replication across 24–48 h 
throughout the system. They hypothesize that this is likely 
through inhibiting IMPa/b1-mediated nuclear import of viral 
proteins. A single dose of ivermectin  can  reduce viral load 
in cell culture to ~5000- fold within 48 h. Ivermectin is FDA 
approved for parasite infections and therefore has the capacity 
for re purposing. Ivermectin is readily available, as it is included 
in the WHO model list of essential medicinal goods.[38]
Antiviral agents
Umifenovir, oseltamivir, arbidol, nitazoxanide
Arbidol, an effective antiviral against SARS-CoV in combination 
with antibiotics (moxifloxacin or levofloxacin, nemonoxacin, 
linezolid, azithromycin or amoxicillin), corticosteroids, and 
oxygen therapy has been used in COVID-19 therapy (Zhang 
et al., 2020) arbidol available in Russia and China. Arbidol 
is given orally to adults at a dosage of 200 mg, 3 times a day. 
Treatment period is no greater than 10 days.[9,22]
Umifenovir is a non-nucleoside broad-spectrum antiviral 
licensed for influenza treatment and prophylaxis in Russia and 
China. Umifenovir is a membrane fusion inhibitor. Current 
regimens of umifenovir used in China include a PO dose of 
200 mg TDS for a duration of 10 days.[39]
Neuraminidase inhibitors are known to reduce viral 
shredding in respiratory secretions and are used for prophylaxis 
against influenza. In a systematic review by Cochrane, Jefferson 
et al. found that oseltamivir declined symptomatic influenza by 
55% and zanamivir by 61%.[40]
Huang et al. (2020) used antibiotics, methylprednisolone 
corticosteroid (40–120 mg/day), and oseltamivir (orally 
75 mg twice daily) in COVID-19 patients along with oxygen 
support. Combination with oseltamivir and other anti-influenza 
medications may be required for coinfections with influenza 
A/B.[13]
Nitazoxanide has demonstrated potent in vitro activity against 
SARS CoV-2, with an EC50 at 48 h of 2.12 μM in Vero E6 cells. 
In comparison to coronaviruses, nitazoxanide demonstrates 
broad spectrum of antiviral behavior in vitro against influenza, 
respiratory syncytial virus, parainfluenza, rotavirus, and 
norovirus among several others. In an outpatient influenza study, 
a 600 mg oral dose of nitazoxanide BID has been strongly linked 
with a ~1-day improved performance in time to symptoms 
resolution compared to placebo (p = 0.008). In a study by Wang 
et al., nitazoxanide was effective against SARS-CoV-2 in vitro.[29]
Antimalarial – chloroquine
Chloroquine is an well known antimalarial agent containing  anti-
inflammatory and immunomodulatory properties. In viruses, 
chloroquine can inhibit pH-dependent stages of replication. 
Furthermore, chloroquine’s immunomodulation is dependent on 
the suppression of cytokines (IL-6 and TNF-α) production and 
dissemination. Moreover, experiments with monkey cell line (Vero 
E6) showed that chloroquine interferes with the receptor glycosylation 
and thereby affects the entry mechanism of SARS-CoV-2.[33]
Yao et al. demonstrated result of a study that chloroquine 
and hydroxychloroquine inhibit SARS-CoV-2 in vitro with 
hydroxychloroquine (EC50=0.72%μM) found to be more 
potent than chloroquine (EC50 = 5.47% μM) in vitro.[41]
These findings have supported the clinical use of chloroquine, 
at a dose of 500 mg by mouth twice daily, in numerous clinical 
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trials in China during this outbreak. An in vivo study by Gao et al. 
demonstrated that chloroquine phosphate is superior to control 
medication to control pneumonia exacerbation, enhance pulmonary 
imaging results, facilitate virus-negative conversion, and reduce 
the duration of disease. Severe adverse reactions to chloroquine 
phosphate were not noted in the aforementioned patients.[29]
Side effects and safety concerns include risk of cardiac 
arrhythmias (e.g., QT prolongation), risk of retinal damage, 
especially with long-term use, caution in patients with G6PD 
deficiency, caution in diabetics, and significant drug interactions.[7]
Antimalarial – hydroxychloroquine
Hydroxychloroquine is formed by addition of hydroxyl group 
to chloroquine. Comparatively  better tolerance is responsible 
for its long term use in rheumatological disorders. Clinical 
safety profile is better than that of chloroquine and allows 
higher daily dose and has fewer concerns about drug-drug 
interactions.[29]
Mechanisms might include suppression of viral enzymes 
or processes such as those of viral DNA and RNA polymerase, 
glycosylation of viral proteins, aggregation of viruses, 
transportation of new virus particles, and release of viruses. 
Certain mechanisms might include cellular receptor inhibition 
of ACE2, surface acidification of the cell membrane hindering 
virus fusion, and cytokine release immunomodulation.[7]
Yao et al. suggested dosing PO hydroxychloroquine 400 mg 
BID for the 1st day and then 200 mg BID for the following 
4 days from in vitro study. Gautret et al. recommended oral 
hydroxychloroquine sulfate 200 mg, 3 times/day during 10 days 
as per their in vivo study.[29,41]
Side effects and safety concerns include risk of cardiac 
arrhythmias, caution in patients with G6PD deficiency, risk 
of retinal damage, especially with long-term use, caution in 
diabetics, and significant drug interactions.[7,13,33]
IFN
IFN-α is a broad-spectrum antiviral that is usually used for the 
treatment of hepatitis. IFNs may stimulate inherent antiviral 
reactions and are anticipated to have in vitro activity against SARS-
CoV-2, considering the previously known activity exhibited 
against MERS-CoV. Chinese guidelines recommend ribavirin 
500 mg IV 2–3 times daily in combination with lopinavir/
ritonavir or inhaled INF-α (5 million units nebulized twice daily) 
as one of the “standard treatment” options for COVID-19.[29]
IFN-α can decrease viral load during the early stage 
of COVID-19 disease and it can help to improve disease 
manifestations and curtail the course of infection; however, 
toxicities are substantial including severe cytopenias, 
hepatotoxicity (including fatality), neuropsychiatric events, and 
risk of developing fatal or life-threatening ischemia or infection.[9]
IFN-α nebulization: 200,000–400,000 IU/kg or 
2–4 μg/kg in 2 ml of sterile water, twice daily for 5–7 days; OR 
IFN-α2b inhalation (puff): Dispensed to high-risk persons in 
close contact with presumed SARS-CoV-2-infected cases or 
those in the early phase with only upper airway expressions. 
Cases should be administered bilaterally 1–2 puffs in the nasal 
cavity, 8–10 puffs in the oropharynx, and 8000 IU per 1–2 h for 
each application, that is, 8–10 puffs/day for 5–7 days.[42]
Conclusion
The latest outbreak of COVID-19 was deemed a pandemic by the 
W.H.O. As of March 24, 2020, COVID-19, as of April 13, 2020, 
COVID-19 has been recognized in 196 countries, with a total of 
1,876,707 laboratory-confirmed cases, 435,591 recovered, and 
116,789 deaths. Till this date, 9352 laboratory-confirmed cases, 
980 recovered, and 324 deaths were reported by Indian Council of 
Medical Research in India. Until now, no effective antiviral drug or 
vaccine has been identified for the treatment of COVID-19. Drug 
repurposing is a highly touted, quick, and price-effective method 
which can resolve the conventional de novo drug discovery and 
innovation obstacles of COVID-19. Passive antibody transfer 
is one of the most effective and traditional tools used in most of 
the infectious outbreaks which is the use of serum of patients who 
just recovered from the active viral infection to treat patients who 
contract in future. Passive antibody transfer has given encouraging 
results against latest outbreak of COVID-19. Wide spectrum 
antiviral drugs such as nucleoside analogs as well as HIV protease 
inhibitors shown to attenuate COVID-19 viral infection in various 
in vitro and in vivo study and are widely used until more definitive 
therapy or vaccine discovery against COVID-19. Drugs such as 
melatonin can serve as a potential supportive treatment along with 
combination of the antiviral drugs lopinavir/ritonavir, Lf has anti-
inflammatory and immunomodulatory against COVID-19, and 
supplementation has been proposed. Vitamins C and D having 
antioxidant properties have been used as supportive treatment 
along with combination of the antiviral. We expect to see 
conclusive drug treatment and vaccine against COVID-19 in the 
anytime soon, until then prevention is the gold standard approach 
against the novel CoV.
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